Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
688526 Wuhan Keqian Biology Co.,Ltd
25.990
+0.160+0.62%
YOY
Do not show
Hide blank lines
(Q9)2022/09/30(Q6)2022/06/30(Q3)2022/03/31(FY)2021/12/31
Total operating revenue
-11.50% 686.52M -27.78% 393.63M -36.46% 202.66M 30.81% 1.1B
Operating revenue
-11.50% 686.52M -27.78% 393.63M -36.46% 202.66M 30.81% 1.1B
Total operating cost
9.21% 367.83M -1.40% 217.25M -15.94% 101.83M 36.05% 452.86M
Operating cost
15.02% 186.04M 7.75% 107.51M 5.58% 54.82M 53.42% 222.76M
Operating tax surcharges
20.41% 4.55M 3.53% 2.77M -6.64% 1.4M 51.99% 6.01M
Operating expense
0.92% 100.46M -11.36% 55.74M -29.27% 23.24M 18.68% 133.92M
Administration expense
-7.37% 55.8M -24.62% 34.67M -53.10% 12.62M 68.85% 74.9M
Financial expense
-1.47% -45.97M -1.39% -29.66M -8.39% -14.18M -98.75% -64.73M
-Interest expense (Financial expense)
199.64% 3.56M 244.86% 3.07M -51.07% 285.62K 324.32% 1.81M
-Interest Income (Financial expense)
7.23% 49.84M 9.04% 33.04M 16.72% 15.98M 100.15% 66.73M
Research and development
17.88% 66.95M 20.82% 46.23M 13.77% 23.94M 35.42% 80M
Credit Impairment Loss
-106.96% -8.68M -111.07% -5.53M 81.11% -1.03M 6.72% -7.85M
Asset Impairment Loss
-365.65% -5.8M -222.84% -1.63M -- -2.01M 59.19% -750.3K
Other net revenue
0 0 0 0
Invest income
8.19% 4.07M 0.88% 2.59M -5.95% 1.15M 28.89% 5.13M
Other revenue
61.43% 14.5M -6.76% 7.32M 332.90% 3.83M -29.16% 14.32M
Operating profit
-27.66% 322.8M -46.05% 179.12M -47.15% 102.76M 26.07% 661M
Add:Non operating Income
105.40% 52.79K 105.40% 52.79K -- -- -76.71% 30K
Less:Non operating expense
-97.08% 49.72K -100.88% -13.42K -490.32% -13.34K -79.42% 983.27K
Total profit
-27.39% 322.8M -45.78% 179.18M -47.14% 102.78M 27.02% 660.05M
Less:Income tax cost
-32.56% 39.56M -54.63% 20.12M -52.87% 12.02M 24.43% 89.41M
Net profit
-26.60% 283.24M -44.41% 159.06M -46.28% 90.76M 27.43% 570.64M
Net profit from continuing operation
-26.60% 283.24M -44.41% 159.06M -46.28% 90.76M 27.43% 570.64M
Less:Minority Profit
-32,010.72% -186.44K -- -53.65K -- -5.95K -- -105.22K
Net profit of parent company owners
-26.56% 283.43M -44.39% 159.11M -46.28% 90.77M 27.45% 570.74M
Earning per share
Basic earning per share
-26.51% 0.61 -45.16% 0.34 -44.44% 0.2 6.03% 1.23
Diluted earning per share
-26.51% 0.61 -45.16% 0.34 -44.44% 0.2 6.03% 1.23
Other composite income
Total composite income
-26.60% 283.24M -44.41% 159.06M -46.28% 90.76M 27.43% 570.64M
Total composite income of parent company owners
-26.56% 283.43M -44.39% 159.11M -46.28% 90.77M 27.45% 570.74M
Total composite income of minority owners
-32,010.72% -186.44K -- -53.65K -- -5.95K -- -105.22K
Currency Unit
CNYCNYCNYCNY
Accounting Standards
CAS (2007)CAS (2007)CAS (2007)CAS (2007)

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
The company was founded in 2001, specializing in veterinary biological products research and development, production, sales and animal epidemic prevention technical services, the company is awarded by the National Development and Reform Commission "National High-tech industrialization demonstration Project" key high-tech enterprises. The company is a biomedical company specializing in the research and development, production and sales of veterinary biological products and animal epidemic prevention technical services, the main products are non-state compulsory immunization pig vaccines and poultry vaccines. The company's main products are non-state compulsory immunization pig vaccines and poultry vaccines. Enterprise honors: the second prize of the National Science and Technology Progress Award, the first prize of Hubei Science and Technology Progress Award, and the national key new products.
CEO: Huanchun Chen
Market: --
Listing Date: 09/22/2020
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist